Get the tools used by (smart)2 investors.

Damodaran's Industry Cost of Equity for Inozyme Pharma Inc

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

INZY: Inozyme Pharma Inc

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The compan...

1.00 USD
Price
USD
Fair Value
Upside
0.98 - 7.79
52-week range

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Inozyme Pharma Inc's Damodaran's Industry Cost of Equity:

INZYHLTH.USAIMDCDNAWINTOLMAVCNX7.0%8.0%9.0%10.0%11.0%

Performance Summary

    How does Inozyme's Damodaran's Industry Cost of Equity benchmark against competitors?

    Hide this widget

    We've identified the following companies as similar to Inozyme Pharma Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

    Metric Usage: Damodaran's Industry Cost of Equity

    Hide this widget
    cost_equity_industry
    Slug
    number
    Datatype
    text
    Format
    current
    Default Period
    Free
    Plan

    To view the full list of supported financial metrics please see Complete Metrics Listing.

    Similar Metrics

    Hide this widget

    Metrics similar to Damodaran's Industry Cost of Equity in the valuation category include:

    View Full List

    Search for metric or datapoint

    Damodaran's Industry Cost of Equity

    A general benchmark for the cost of equity in an industry based on research by Professor Damodaran at New York University, Stern.

    Definition of Damodaran's Industry Cost of Equity

    Hide this widget
    A general benchmark for the cost of equity in an industry based on research by Professor Damodaran at New York University, Stern.

    Sector Benchmark Analysis

    Sector
    Industry Group
    Industry
    Hide this widget
    8.3%8.8%9.2%10.0%51525

    The chart above depicts the distribution of damodaran's industry cost of equity for companies operating in the Healthcare sector in the Developed economic region. Over 60 companies were considered in this analysis, and 68 had meaningful values. The average damodaran's industry cost of equity of companies in the sector is 9.1% with a standard deviation of 0.8%.

    Inozyme Pharma Inc's Damodaran's Industry Cost of Equity of - is significantly outside the interquartile range and is excluded from the distribution. The following table provides additional summary stats:

    Damodaran's Industry Cost of Equity In The Healthcare Sector
    Economic Risk RegionDeveloped
    Total Constituents68
    Included Constituents68
    Min7.2%
    Max10.0%
    Median9.1%
    Mean9.1%
    Standard Deviation0.8%

    You can find companies with similar damodaran's industry cost of equity using this stock screener.

    All rights reserved. Terms Of Use